# Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

> **NCT04805307** · PHASE1 · COMPLETED · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 176 (actual)

## Conditions studied

- Advanced Solid Tumor
- Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
- Pancreatic Cancer

## Interventions

- **DRUG:** CMG901

## Key facts

- **NCT ID:** NCT04805307
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-24
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-04-05
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805307, "Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04805307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*